Skip to main content
x

Recent articles

AACR 2026 – Matisse pains a mixed picture for Innate

IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.

AACR 2026 – Moderna touts first-line data

The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.

Ominous signs for EGFR degraders

BeOne's degrader BG-60366 appears to have been discontinued.

ASCO 2026 preview – Revolution completes its rout

Daraxonrasib scores a plenary session late-breaker.

Gilead edges further away from Arcus

The disclosure comes as another of Arcus's TIGIT trials flops.

AACR 2026 – a CCR8 reality check

Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.